Quest Diagnostics Inc. Stock Underperforms Wednesday When Compared To Competitors

Quest Diagnostics Inc. (DGX) shares fell 2.05% to $201.77 on Wednesday, underperforming the broader market as the S&P 500 and Dow Jones rose. This marks the stock's ninth consecutive day of losses, leaving it 7.95% below its 52-week high. While competitors like UnitedHealth and IQVIA also declined, Quest's drop was more pronounced.

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Quest Diagnostics Inc. (DGX) slipped 2.05% to $201.77 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.38% to 7,572.40 and the Dow Jones Industrial Average rising 0.29% to 52,658.64.

This was the stock's ninth consecutive day of losses.

Quest Diagnostics Inc. closed 7.95% short of its 52-week high of $219.20, which the company reached on July 7th.

The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as UnitedHealth Group Inc. (UNH) fell 1.57% to $418.52, IQVIA Holdings Inc. (IQV) fell 0.49% to $206.81, and Centene Corp. (CNC) fell 3.07% to $66.61.

Data source: Dow Jones Market Data, FactSet. Data compiled July 15, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

07-15-26 1703ET